Fuel Clinical Drives Late-Stage Endocrinology Study Rescue Through Integrated Biometrics, Data and Database Lock Execution
Cross-functional clinical, data, biostatistics and programming intervention preserves subject evaluability, critical endpoints and the integrity of final study outputs
Published: July 2026
TORONTO — Fuel Clinical today announced the successful execution of a complex clinical study rescue within the endocrinology and metabolic disease space, helping stabilize a late-stage program, preserve the analytical value of enrolled subjects, resolve critical data and statistical issues, and drive the study through database lock and final reporting activities.
The intervention began when senior sponsor personnel identified a series of emerging risks across the study and recognized that additional integrated clinical, data and biometrics expertise was required to protect the program. Fuel was brought in to work hand in hand with the sponsor's leadership team, first to understand the issues at both the subject and study level, and then to jointly define and execute a remediation plan.
That partnership became central to the rescue effort. Sponsor leadership brought deep knowledge of the program, its history and its scientific objectives, while Fuel added integrated expertise across Clinical Operations, Data Management, Biostatistics, Statistical Programming and study reporting. Together, the teams worked through the issues systematically and aligned around a shared objective: preserve the integrity of the study and the analytical value of the subjects wherever possible.
At that point, the challenge was no longer simply completing outstanding study activities.
The priority was determining whether the enrolled subjects, critical endpoints and underlying study data could still be preserved for meaningful analysis.
Fuel and the sponsor jointly evaluated the study from the end backward, beginning with the requirements for final analysis and the Clinical Study Report.
That review identified a series of issues requiring immediate intervention, including subject-level data discrepancies, unresolved central laboratory data, endpoint concerns, programming deficiencies, inconsistencies within tables, listings and figures, and gaps in the execution of the Statistical Analysis Plan.
Protecting the Analytical Value of Every Subject
For Fuel, one of the most important objectives was preserving the inclusion of subjects wherever the protocol, data and statistical framework allowed.
Each subject represented a substantial clinical, operational and financial investment. Losing subjects unnecessarily from an analysis population because of preventable data, reconciliation or programming issues would have directly reduced the value of the study.
Fuel therefore reviewed subject-level data, eligibility considerations, endpoint requirements, protocol deviations, laboratory information and analysis population criteria to determine where issues could be corrected, reconciled or appropriately addressed before final analysis.
This approach reflects Fuel Clinical's Analysis Viable Subjects™ philosophy: the objective is not simply to enroll and complete subjects, but to maximize the number of subjects whose data can meaningfully contribute to the intended analyses.
When we entered the program, there were issues across multiple parts of the study that had the potential to affect subject evaluability and the final analysis. Our first priority was to understand the study at the subject level, determine what the data actually supported, and identify where issues could still be corrected before they affected the integrity of the final outputs. Every viable subject matters, particularly when significant clinical and financial investment has already gone into generating that data.
Erika Passi
|Global Head of Biometrics, Fuel Clinical
Driving Database Lock Readiness
Fuel established a coordinated database lock plan that connected Data Management, Clinical Operations, laboratory reconciliation, Biostatistics and Statistical Programming around a single definition of analysis-ready data.
Activities included:
- database lock planning and execution;
- subject-level data review and clean-up;
- central laboratory reconciliation;
- endpoint review and preservation;
- protocol deviation review;
- query identification and resolution;
- data consistency review;
- drug inventory and accountability reporting;
- analysis population review;
- Statistical Analysis Plan execution review;
- Biostatistics oversight;
- Statistical Programming remediation;
- TLF review, correction and regeneration;
- analysis dataset review;
- final data quality review;
- Clinical Study Report preparation and related reporting activities;
Rather than treating database lock as a Data Management milestone alone, Fuel approached it as an integrated clinical and statistical event.
That distinction was critical.
A database can technically be locked while significant issues remain in analysis populations, endpoint derivations, statistical programming or final outputs. Fuel's objective was to ensure that database lock represented genuine analysis readiness, not simply the end of data entry.
Correcting Biostatistics and Programming Issues
Fuel's Biostatistics and Statistical Programming teams performed a detailed review of the existing statistical approach, datasets and outputs.
The review identified programming and execution issues requiring correction before final study conclusions could be relied upon.
Fuel worked through the affected analyses, corrected programming deficiencies, reviewed derivations and analysis populations, and rebuilt or revised tables, listings and figures where necessary.
The team also evaluated execution against the Statistical Analysis Plan to identify inconsistencies between the planned analyses and the outputs being generated.
Late-stage statistical and programming issues can be particularly consequential because they may not become fully visible until a study is already approaching database lock or final reporting. At that stage, Data Management, Biostatistics and Programming need to be working from the same subject-level understanding of the study. We focused on preserving valid endpoints and analysis populations, correcting the programming and outputs where required, and ensuring the final results accurately reflected the underlying study data.
Erika Passi
|Global Head of Biometrics, Fuel Clinical
From Study Clean-Up to CSR Readiness
Following the data and statistical remediation work, Fuel remained engaged through the final stages of the program, including database lock execution, analysis, output generation and Clinical Study Report activities.
This continuity was important because decisions made during data clean-up had direct implications for analysis populations, endpoint interpretation, statistical outputs and final study reporting.
Fuel's integrated approach allowed those decisions to remain connected from the subject level through to the final report.
The engagement demonstrates Fuel Clinical's Unified Intelligence model in practice: bringing clinical, operational, biometrics, data and technology expertise together around the information ultimately required to reach a defensible study conclusion.
This type of program demonstrates why these disciplines cannot operate in isolation. The protocol, the subject data, the laboratory data, the endpoints, the statistical plan, the programming and the final reporting all have to connect. When they do, you have the opportunity not only to correct problems, but to preserve the analytical value of the study and the contribution of the subjects who participated in it.
Erika Passi
|Global Head of Biometrics, Fuel Clinical
About Fuel Clinical
Fuel Clinical's services begin with Unified Intelligence Strategic Planning, helping sponsors start with the end in mind by defining the clinical, operational, biometrics, data and technology strategy required to achieve a successful study outcome.
From that foundation, Fuel provides integrated Clinical Development and Clinical Operations, Data Management, Biostatistics and Statistical Programming, Data Analytics, Safety and Pharmacovigilance, and a comprehensive suite of eClinical technologies including EDC, RTSM/IWRS, CTMS, eTMF, ePRO/eCOA, Safety Database and Clinical Trial Payments solutions.
Through its Unify platform, Fuel connects these capabilities and critical study data within a coordinated environment, giving sponsors greater visibility into study performance and the information required to make timely, informed decisions throughout development.